Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Research Site, Duarte, California, United States

Research Site, Los Angeles, California, United States

Research Site, Sacramento, California, United States

Research Site, Santa Monica, California, United States

Research Site, New Haven, Connecticut, United States

Research Site, Chicago, Illinois, United States

Research Site, Baltimore, Maryland, United States

Research Site, Boston, Massachusetts, United States

Research Site, Boston, Massachusetts, United States

Research Site, Grand Rapids, Michigan, United States

Research Site, New York, New York, United States

Research Site, New York, New York, United States

Research Site, Portland, Oregon, United States

Research Site, Pittsburgh, Pennsylvania, United States

Research Site, Houston, Texas, United States

Research Site, Seattle, Washington, United States

Research Site, Odense C, Denmark

Research Site, Catania, Italy

Research Site, Naples, Italy

Research Site, Orbassano, Italy

Research Site, Padova, Italy

Research Site, Varese, Italy

Research Site, Chūōku, Japan

Research Site, Fukuoka, Japan

Research Site, Kōtoku, Japan

Research Site, Nagoya, Japan

Research Site, Osaka, Japan

Research Site, Wakayama, Japan

Research Site, Amsterdam, Netherlands

Research Site, Amsterdam, Netherlands

Research Site, Maastricht, Netherlands

Research Site, Nijmegen, Netherlands

Research Site, Rotterdam, Netherlands

Research Site, Drammen, Norway

Research Site, Oslo, Norway

Research Site, Trondheim, Norway

Research Site, Seongnam-si, South Korea

Research Site, Seoul, South Korea

Research Site, Seoul, South Korea

Research Site, Seoul, South Korea

Research Site, A Coruña, Spain

Research Site, Barcelona, Spain

Research Site, Barcelona, Spain

Research Site, Madrid, Spain

Research Site, Madrid, Spain

Research Site, Seville, Spain

Research Site, Stockholm, Sweden